Can I use bacitracin and plecanatide together?

Theoretically yes, since they target different body systems (topical antibiotic vs. oral GI prokinetic). However, this combination would be unusual in clinical practice. Use only under medical supervision if recommended by a healthcare provider for separate conditions.

Is bacitracin still used despite being from the 1940s?

Yes. Bacitracin remains widely recommended for minor wound care due to cost, accessibility, safety record, and efficacy. Its long history and over-the-counter availability make it a first-line topical antibiotic for consumers and healthcare providers globally.

Why did plecanatide take so long to approve after discovery?

Plecanatide required extensive Phase 2 and Phase 3 clinical trials to establish efficacy in CIC and IBS-C populations. Regulatory approval timelines for new molecular entities typically span 10–15 years from discovery to FDA approval, reflecting rigorous safety and efficacy requirements.

Which is more expensive, bacitracin or plecanatide?

Bacitracin is significantly cheaper—often $3–8 over-the-counter. Plecanatide, a brand-name prescription therapy, typically costs $200–400 monthly before insurance. Cost-benefit varies based on indication and insurance coverage.

Are there alternatives to plecanatide for constipation?

Yes. First-line options include osmotic laxatives (polyethylene glycol), stool softeners (docusate), and fibre supplements. Other prescription alternatives include linaclotide (another GC-C agonist) and prucalopride. Plecanatide is reserved for patients who haven't responded to these.

Bacitracin vs Plecanatide: Key Differences Explained

Bacitracin and Plecanatide are both FDA-approved peptides, but they work in completely different ways and treat different conditions. Bacitracin is an antibiotic peptide that has been used since the 1940s to prevent bacterial infections in wounds and eyes. Plecanatide, approved much more recently (2019), is a guanylate cyclase-C (GC-C) receptor agonist designed to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). While both are peptide-based medicines, their mechanisms, clinical applications, and patient populations are distinct. Understanding these differences helps clarify which compound serves which therapeutic purpose.

What Is Bacitracin?

Backtracin is a polypeptide antibiotic originally isolated from the bacterium Bacillus subtilis. It has been FDA-approved since 1948 and remains one of the most widely used topical antibiotics globally. The compound works by inhibiting bacterial cell wall synthesis, making it effective against a broad spectrum of gram-positive bacteria.

Clinically, bacitracin is formulated as an ointment, eye ointment, or powder for topical application. Over 40 clinical trials have evaluated bacitracin in various wound care and infection prevention contexts. It's available over-the-counter in many countries without prescription, making it accessible for minor cuts, scrapes, and burns.

The regulatory landscape for bacitracin is straightforward: it's approved in the US by the FDA, approved in Canada by Health Canada, and has a long history of use in European nations, though it lacks formal EMA authorisation as a centralised procedure drug.

What Is Plecanatide?

Plecanatide is a synthetic peptide that activates the guanylate cyclase-C receptor, a target found on intestinal cells. The FDA approved plecanatide (brand name Trulance) in December 2018 for chronic idiopathic constipation, and subsequently approved it for IBS-C in 2019.

Unlike bacitracin's antibacterial action, plecanatide works by increasing fluid secretion into the intestine and promoting gut motility. When the GC-C receptor is activated, it triggers an increase in cyclic guanosine monophosphate (cGMP), which relaxes intestinal muscles and enhances bowel movement.

Plecanatide has been evaluated in 14 clinical trials, with landmark studies showing significant efficacy in patients with CIC and IBS-C. It's approved by the FDA and Health Canada but, like bacitracin, lacks EMA authorisation.

Clinical Evidence: Bacitracin

Backtracin's evidence base spans more than seven decades. A systematic review in the Cochrane Database of Systematic Reviews examined topical antibiotics for wound infection prevention, concluding that bacitracin-based ointments significantly reduce infection rates in minor wounds compared to no treatment or placebo.

The compound is particularly valued for:

Wound care: Preventing infection in lacerations, abrasions, and minor surgical wounds
Eye health: Bacitracin ophthalmic ointment treats bacterial conjunctivitis and prevents infection in eyes
Burn treatment: Topical application reduces bacterial colonisation in minor burns

Because bacitracin is topical and poorly absorbed systemically, adverse effects are minimal. The main risk is localised allergic contact dermatitis in sensitive individuals, which occurs in fewer than 1% of users.

Clinical Evidence: Plecanatide

The pivotal Phase 3 trial for plecanatide in CIC (ACCEPT trial) showed that 39.1% of patients on plecanatide achieved ≥3 spontaneous bowel movements (SBMs) per week, compared to 17.6% on placebo. For IBS-C, the Phase 3 AOIFE-2 trial demonstrated a 27.1% response rate on plecanatide vs 14.0% on placebo.

These results position plecanatide as an effective oral therapy for patients who haven't responded to first-line treatments like fibre, osmotic laxatives, or stool softeners. Evidence grade ratings place plecanatide at Grade A for both indications.

Common side effects include diarrhoea (more frequent in early treatment), abdominal pain, and nausea. Unlike bacitracin, plecanatide is absorbed systemically and requires monitoring for tolerability.

Key Mechanistic Differences

The fundamental difference lies in how each compound works:

Bacitracin = Antibacterial (kills or inhibits bacteria via cell wall disruption)

Plecanatide = Prokinetic/secretagogue (enhances intestinal fluid and motility via GC-C receptor)

This distinction means the two compounds cannot be directly compared for efficacy—they solve different problems. Bacitracin addresses infection; plecanatide addresses constipation.

Regulatory Status Comparison

| Compound | FDA | Health Canada | EMA | |----------|-----|---------------|-----| | Bacitracin | Approved (1948) | Approved | Not authorised | | Plecanatide | Approved (2018) | Approved | Not authorised |

Both compounds hold FDA and Health Canada approval, indicating strong safety and efficacy evidence under North American regulatory scrutiny. Neither has received centralised EMA approval, though bacitracin has decades of use and acceptance in European practice settings.

Who Should Use Bacitracin?

Backtracin is ideal for:

Minor wound care: Small cuts, scrapes, and abrasions requiring infection prevention
Post-procedure wound management: Minor surgical or dermatological procedure aftercare
Eye infections: Bacterial conjunctivitis or prevention of secondary infection
General consumers: Over-the-counter availability makes it accessible for self-care
Individuals seeking topical-only treatment: Those who cannot or prefer not to use systemic antibiotics

Backtracin is not suitable for:

Serious or deep infections (requires systemic antibiotics and medical evaluation)
Intestinal or digestive concerns
Patients with known bacitracin allergy or severe contact dermatitis history

Who Should Use Plecanatide?

Plecanatide is designed for:

Chronic idiopathic constipation patients who haven't responded to osmotic laxatives, stool softeners, or dietary fibre
IBS-C patients seeking targeted bowel motility enhancement
Individuals with functional GI disorders who need a non-antibiotic, non-stimulant laxative
Prescription-eligible adults (generally those with access to healthcare providers)

Plecanatide is not suitable for:

Acute constipation (not indicated; first-line treatments are more appropriate)
Patients with known plecanatide allergy
Those with mechanical bowel obstruction or severe dehydration
Individuals under 18 years of age (safety not established)

Overlap and Distinctions

While both are approved peptides, there is no clinical overlap between bacitracin and plecanatide:

Bacitracin users won't benefit from plecanatide (different system targeted)
Plecanatide users won't benefit from bacitracin (wrong mechanism for constipation)
A person could theoretically use both for different indications simultaneously without direct interaction, though this scenario is rare

The comparison is more educational—understanding what makes each unique—rather than practical substitution.

Regulatory and Access Differences

Backtracin's long approval history and over-the-counter status mean minimal friction for access. Plecanatide, as a newer drug requiring a prescription, involves a longer decision pathway: diagnosis confirmation, provider consultation, and insurance coverage evaluation.

Both compounds support robust clinical trial literature. Bacitracin's 40+ clinical trials reflect decades of continued research and application refinement. Plecanatide's 14 trials represent more concentrated, modern investigation for a single indication.

Cost and Availability

Backtracin ointment is inexpensive and widely available without prescription in pharmacies and supermarkets across North America. Plecanatide is a prescription medication covered variably by insurance depending on prior authorisation requirements and formulary placement. Pricing reflects the gap between a century-old generic antibiotic and a branded GC-C agonist.

Safety Profiles

Both compounds carry Grade A evidence ratings, signifying rigorous clinical evaluation.

Bacitracin safety: Topical use = minimal systemic absorption and adverse effects. Main risk is localised contact dermatitis.

Plecanatide safety: Oral systemic therapy = monitored tolerability. Most common side effect is diarrhoea, particularly during treatment initiation. Long-term safety data from post-marketing surveillance continues to accumulate.

Final Thoughts

Backtracin and plecanatide represent two distinct therapeutic paradigms: one an ancient antibiotic for infection prevention, the other a modern GI prokinetic for constipation management. Comparing them is less about choosing one over the other and more about understanding which solves which clinical problem.

For wound care and infection prevention, bacitracin remains the accessible, evidence-backed choice. For chronic constipation unresponsive to first-line agents, plecanatide offers a targeted, prescription-strength alternative backed by contemporary clinical trials.

Consult a healthcare provider to determine which, if either, is appropriate for your specific situation.

Bacitracin vs Plecanatide: A Clear Comparison